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Background: Selective pressure from either the immune response or the use of nucleoside analogs in antiviral
therapy could be driving the emergence of HBV mutants. Because of the overlap of the open reading frame (ORF)
S for the HBsAg and ORF P for viral polymerase, rtM204I and rtM204V mutations in the polymerase would produce
sI195M and sW196S in the HBsAg. The combined effects of immune-escaped mutations (sT118M, sG145K, sG145R)
and drug-resistant mutations (rtM204I, rtM204V) on the antigenicity profiles of HBsAg has not been widely explored.
Methods: To determine the combined effects of immune-escaped and drug-resistant mutants on the antigenicity
profiles of HBsAg, recombinant plasmids encoding HBsAg double mutants were constructed using site-directed
mutagenesis. The supernatant from each plasmid transfection was analyzed for HBsAg in the western-blotting and
five of the most commonly used commercial ELISA kits in China.
Results: Western-blotting assay showed the successful expression of each HBsAg mutant. All five ELISA kits
manifested similar avidity, which were demonstrated by the slope of the curves, for the sT118M mutant, and
sT118M-rtM204I (sT118M-sI195M) and sT118M-rtM204V (sT118M-sW196S) double mutants, suggesting that
drug-resistant YMDD mutants caused negligible losses in the antigenicity of immune-escaped sT118M HBsAg. In
contrast, the presence of the rtM204I (sI195M) mutation, but not rtM204V (sW196S) in combination with the sG145K
mutation significantly reduced the avidity of sG145K HBsAg. The rtM204I (sI195M) mutation also decreased the
antigenicity profiles for sG145R HBsAg.
Conclusions: Drug-resistant mutations rtM204I (sI195M) and rtM204V (sW196S) caused significant reduction in
antigenicity for the immune-escaped HBsAg mutants sG145K and sG145R, which may hamper HBV diagnosis and
disease control from HBV blood-transfusion transmissions in China. The development of ELISA kits with a greater
sensitivity for drug-resistant and immune-escaped HBsAg warrants further consideration.
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The implementation of the Hepatitis B Immunization
program in China resulted in a decrease in the incidence
of HBV infections, from approximately 10% to 7% in the
general population [1]. However, hepatitis B still remains
endemic in China and other parts of Asia [2,3]. Blood
screening strategies used in other developed countries* Correspondence: caixubing@sina.com; zhhuang@njmu.edu.cn
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reproduction in any medium, provided the orwith a reported low incidence of HBV infection include
HBsAg and anti-HBc screening, and in some instances
nucleic acid testing (NAT) [4-6]; whilst China relies
almost solely on HBsAg serologic screening [7,8]. HBsAg
mutations may give rise to changes in HBsAg antigenic-
ity, resulting in reduced sensitivity and detection capabi-
lity of current diagnostic tests, and which might present
a challenge for HBsAg screening and HBV diagnosis,
and ultimately increase the risk of transfusion-
transmission of HBV infection [7-10].
In the absence of a proof-reading function, HBV reverse
transcriptase randomly misincorporates bases into theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Western blot analysis of the HBsAg expressed by wild
type and mutant clones, plus empty vector as a negative
control. Transfected 293 T cell supernatant samples (10 μl/sample)
were loaded to each lane in SDS-PAGE. HBsAg specific monoclonal
antibody H166 was used as the detection antibody at 1:1000
dilution. 1: wild type; 2: sT118M; 3: sT118M-rtM204I; 4: sT118M-
rtM204V; 5: sG145K; 6: sG145K-rtM204I; 7: sG145K-rtM204V; 8: sG145R;
9: sG145R- rtM204I; 10: sG145R- rtM204V; 11: empty vector.
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with a large number of variants [11]. Meanwhile, selection
pressure from the specific immune response, whether
from the passive application of hyperimmune globulin
(HBIG) prophylaxis [12] or from active HBsAg vaccin-
ation [13,14], could drive the emergence of HBsAg mutant
viruses. An amino acid change from glycine to arginine at
position 145 (sG145R) for the immunodominant deter-
minant of HBsAg, which alone can be responsible for
vaccine escape, is most commonly reported and has been
well documented [7,15]. A glycine to lysine point muta-
tion at position 145 (sG145K) or a threonine to methio-
nine substitution at position 118 (sT118M) has also been
detected, and both mutations have been reported to sig-
nificantly change the antigenic profile of HBsAg compared
with that of wild type [7,16-18].
HBV mutants could also evolve because of selective
pressure from nucleoside analog treatments. Lamivudine
was the first approved oral nucleoside analogue for the
treatment of chronic HBV infection, suppressing HBV
replication by interfering with HBV DNA polymerase
[19-21]. The substitution of methionine by isoleucine (I)
or valine (V) in the tyrosine-methionine-aspartate-aspar-
tate (YMDD) motif (C domain) at position 204 (rtM204I
or rtM204V) has been shown to confer lamivudine
resistance on HBV [22-24]. Interestingly, because of the
overlap of the open reading frame (ORF) S for the
HBsAg and ORF P for viral polymerase, rtM204I and
rtM204V mutations produce sI195M and sW196S in
the HBsAg [25,26]. Consequently, the YMDD muta-
tion can occur naturally in chronic HBV infections in
the absence of previous exposure to lamivudine treat-
ment [27,28], highlighting the overlap of selective
pressure between the immune response and drug
treatment.
The double mutations may develop if the chronic
HBV patients, who have been infected with immune-
escaped mutant, receive anti-virus therapy or even in the
absence of previous exposure to lamivudine treatment.
Immune-escaped and drug-resistant mutants may also
occur in some patients, who have been infected with
drug-resistant mutants but been false negative in the
HBsAg screening for the reduced antigenicity of the
mutant S protein and receive hyperimmune globulin
prophylaxis or HBsAg vaccination. Although substitu-
tions outside of the ‘a’ determinant appear to be readily
detected by current commercially available HBsAg im-
munoassays, there is limited information as to the com-
bined effects of immune-escaped (T118M, G145K,
G145R) and drug-resistant (rtM204I = sI195M, rtM204V =
sW196S) point mutations on the antigenicity profiles
of HBsAg. In the present study, we produced HBsAg
double mutants (immune-escaped and drug-resistant)
using site-directed mutagenesis and analyzed theirbinding capability using five commercially available
ELISA kits in China.
Results
Expression of HBsAg mutants
To examine whether HBsAg mutants could express
properly, 293 T cells were transfected transiently with
each HBsAg mutant clone. With the wild-type HBsAg
clone as the positive control and a mock DNA vector as
the negative control, the expression of HBsAg mutants
in 293 T cells was examined by Western blotting assay
using monoclonal antibody H166, which recognized the
amino acid 121–124 loop of HBsAg as a continuous epi-
tope. These results indicated that 293 T cells transfected
with either wild-type or HBsAg mutants had very com-
parable levels of HBsAg production (Figure 1). Since
SDS denatured all proteins into linear shape, the overall
antigenicity of proteins, including the configuration
epitopes and linear epitopes, could not be loyally proved
in the Western-blotting assay. Different from Western-
blotting, ELISA is usually done to detect antigens in
their native state, which reflects the antigenicity better.
Negligible decline in the antigenicity of sT118M-rtM204I
or sT118M-rtM204V mutant
Of the five commercial HBsAg ELISA kits used in this
study, four kits (LZ, WT, GBT, and BN) recognized the
sT118M immune-escaped mutant and recombinant
sT118M-rtM204I (sT118M-sI195M) mutant, yielding
similar titration curves, and indicating that rtM204I may
contribute marginally to the antigenicity of sT118M
HBsAg. Similarly, the differences in avidity (as deter-
mined by the slope of the curve) was indistinguishable
Figure 2 (See legend on next page.)
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Figure 2 The supernatants from each plasmid transfection were analyzed for HBsAg using five ELISA kits. (A) Zhu Hai LivZon Diagnostic
INC (LZ); (B) Beijing WanTai Biological Pharmacy Enterprise Limited Company (WT); (C) Beijing Big-GBI Biotech Limited Company (GBI); (D) Beijing
BioNeovan Limited Company (BN); and (E) Shenzhen Kang Sheng Bao Bio-Technology Limited Company (KSB). With the exception of ELISA kit
KSB, which recognized sT118M-rtM204I (sT118M-sI195M) with reduced avidity, all of the kits had almost invariable slope or avidity to the sT118M
mutant, sT118M-rtM204I (sT118M-sI195M), and sT118M-rtM204V (sT118M-sW196S) double mutant. *, p < 0.05, compared with sT118M HBsAg.
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(sT118M- sW196S) mutant for all five assays, suggesting
that drug-resistant YMDD mutants caused a negligible
loss in antigenicity for immune-escaped sT118M HBsAg
(Figure 2).
Significant reduction in the antigenicity of sG145K-rtM204I
HBsAg mutant
As with the recently identified T118M mutation in the
‘a’ determinant of HBsAg [7], the occurrence of sG145K
or sG145R mutants are well reported [16-18], and they
therefore may have a more significant role in infection
diagnosis. With the rtM204I (sI195M) mutation on the
backbone of the immune escape mutant sG145K, avidity
was reduced significantly for four of the ELISA kits. The
exception was with the GBI ELISA kit. These results
suggest that unlike sT118M HBsAg, rtM204I (sI195M)
may cause a considerable reduction in the antigenicity of
sG145K mutant HBsAg. However, the rtM204V (sW196S)
mutation, failed to cause a reduction in avidity in the five
ELISA kits tested (Figure 3).
Decrease in the antigenicity of sG145R-rtM204I/V HBsAg
mutant
The antigenicity profile also decreased for sG145R HBsAg
when coupled with mutation rtM204I (sI195M) for all of
the ELISA kits. Interestingly, rtM204V (sW196S) muta-
tion also decreased the antigenicity of sG145R HBsAg but
only for the WTand BN ELISA kits (Figure 4).
Discussion
Currently, there are three lines of defense for HBsAg
screening in transfusion centers across China. The first
line of defense is the fast colloidal gold assay, which is
performed prior to blood donation. Two rounds of
screening using the more sensitive ELISA, using two
commercially available kits from different companies,
constitutes the two latter lines of defense [7]. Despite
the current screening practices, post-blood transfusion
HBV infection still persists [29,30], most probably due
to the serologically negative window period (more so
during the late stages of infection) [31], or through treat-
ment [26]; all of which highlight the need for HBcAb
screening and NAT in China. Unfortunately, HBcAb
screening is hampered by the high prevalence of HBV
infection in China. Although nationwide implementation
of triplex-individual-donation-NAT testing for HBVDNA would detect an additional 9964 viremic donations
per year in China [32], NAT is procedurally cumbersome
and incurs high costs, and is therefore more suitable for
developed countries with a low prevalence of HBV infec-
tion [33]. As HBsAg screening is fundamentally the only
strategy which can be used to reduce post-transfusion
HBV infection in China, the antigenicity of HBsAg,
especially to mutants, should be explored further.
HBsAg mutants can evolve from either selective pres-
sure from the immune response or through nucleoside
analog treatments [34]. Although the 'a'-determinant
region of HBsAg was usually unaffected by lamivudine
therapy [35], mutations of amino acids outside the 'a'-
determinant region could alter the antigenicity of
HBsAg, especially considering their roles on the con-
formational changes of HBsAg. The unique gene struc-
ture of HBV dictates that variation within the shared
coding region for HBsAg and virus polymerase may have
an indirect affect on the other. This was demonstrated
with the mutation sW196S in HBsAg, which was asso-
ciated with reduced binding to anti-HBs antibody, and
corresponding to rtM204I in polymerase and conferring
resistance to lamivudine [36].
Regarding the co-existence of immune-escaped mutants
and drug-resistant mutants, it is plausible to investigate
their combined influence on the antigenicity of HBsAg.
The immune escape mutant sT118M HBsAg can decrease
the antigenicity of HBsAg considerably [37]. In the current
study no changes to the antigenicity of sT118M HBsAg
was observed when the drug-resistant mutants rtM204I
(sI195M) or rtM204V (sW196S) were present on the
sT118M backbone. YMDD mutations, particularly
rtM204I (sI195M), reduced the antigenicity of sG145K
HBsAg significantly, causing the great drop in the slope of
an antibody titration curve in four of the five ELISA kits.
The presence of rtM204I (sI195M) on the sG145R HBsAg
mutant backbone, also resulted in a loss in avidity of
ELISA kits or the antigenicity of HBsAg. Compared
with rtM204I (sI195M), the YMDD mutation rtM204V
(sW196S) appeared to have minimal influence on the
immune-escaped HBsAg mutants. rtM204I (sI195M) sig-
nificantly reduced the antigenicity of immune-escaped
HBsAg, especially for the most common mutants sG145K
and sG145R HBsAg. Of great concern is the possibility
that escaped HBV mutants which may be not neutralized
by antibodies induced by current HBsAg vaccines and
unable to be detected using current HBsAg screening
Figure 3 The supernatants from each plasmid transfection were analyzed for HBsAg using five ELISA kits. (A) Zhu Hai LivZon Diagnostic
INC (LZ); (B) Beijing WanTai Biological Pharmacy Enterprise Limited Company (WT); (C) Beijing Big-GBI Biotech Limited Company (GBI); (D) Beijing
BioNeovan Limited Company (BN); and (E) Shenzhen Kang Sheng Bao Bio-Technology Limited Company (KSB). With the rtM204I (sI195M)
mutation in the backbone of sG145K, avidity was reduced significantly in four kits. The exception was with ELISA kit GBI. rtM204V (sW196S)
mutation did not cause antigenic variation of sG145K HBsAg. *, p < 0.05, compared with sG145K HBsAg.
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Figure 4 The supernatants from each plasmid transfection were analyzed for HBsAg using five ELISA kits. (A) Zhu Hai LivZon Diagnostic
INC (LZ); (B) Beijing WanTai Biological Pharmacy Enterprise Limited Company (WT); (C) Beijing Big-GBI Biotech Limited Company (GBI); (D) Beijing
BioNeovan Limited Company (BN); and (E) Shenzhen Kang Sheng Bao Bio-Technology Limited Company (KSB). With the rtM204I (sI195M)
mutation in the backbone of sG145R, avidity was reduced significantly for all ELISA kits. rtM204V (sW196S) mutation also reduced the recognition
of sG145R HBsAg in ELISA kits WT and BN. *, p < 0.05, compared with sG145R HBsAg.
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viduals [26] who are blood donors in China.Conclusions
Drug-resistant YMDD mutations caused a significant
reduction in the antigenicity of immune-escaped HBsAg,
particularly for the most common mutant sG145K. The
consequences of these results are that a reduction in
HBsAg antigenicity may hinder HBsAg diagnosis and
consequently increase the risk of HBV blood-transfusion
transmission in China. To reduce the transmission of
HBV through blood transfusions, HBsAg ELISA kits
with greater analytic sensitivity and detection capability
for wild type HBsAg and diverse mutants should be
developed.Materials and methods
Construction of plasmids encoding double mutant HBsAg
by site-directed mutagenesis
Plasmid pJW4303 incorporating the optimized wild-type
HBsAg gene (genotype B) was a gift from China-US
Vaccine Research Center [38]. Site-directed mutagenesis
of the HBsAg was achieved using the Altered Sites in vitro
Mutagenesis Kit (Promega Corporation, Madison, WI.)
according to the manufacturer’s instructions, and the
primers listed in Table 1. Mutations were verified by
sequencing prior to cloning into similarly digested empty














rtM204M/I-Backward 5’-ACGGACAGCCACACGGTGGGGCTCA-3’experiments were purified using Qiagen’s plasmid midi kit
(Qiagen Inc., Chatsworth, CA.).
Table 1 Primers for site-directed mutagenesis.
Transient transfection with the expression plasmids
Human embryonic kidney 293 T cells were maintained
in high-glucose DMEM (Gibco) supplemented with 10%
fetal calf serum (Hyclone) and 1 X Pen/Strep (Sigma) in
6-well tissue culture plates at 37°C and 5% CO2. Once
the cells had reached 60 to 80% confluence they were
transfected with recombinant plasmid DNA using
PolyFect transfection reagent (Qiagen) according to a
previously described method [39]. Briefly, 2 μg plasmid
was mixed with 20 μl PolyFect transfection reagent and
incubated at room temperature for 5–10 min before
addition to 293 T cells. The culture supernatant of
transfected cells was collected after 72 h and stored
at −70°C until required for the detection of HBsAg.
Western-blotting
To identify the expression of HBsAg construct, the cul-
ture supernatant from each HBsAg mutant transfected
cells was subjected to SDS-PAGE and blotted onto PVDF
membrane. Blocking was done with 0.1% I-Block (Tropix,
Bedford, MA). The membrane was incubated with H166
anti-HBs from Abbott at 1:1000 dilution for 1 h and
reacted subsequently with AP-conjugated goat anti-mouse
IgG at 1:5000 dilution for 30 min. Membranes were
washed with blocking buffer after each step. Western-light
substrate was then applied to the membrane for 5 min.
X-ray films were exposed to the membrane and devel-
oped by a Kodak processor.
Elisa
The supernatants recovered from each transfection were
serially diluted and analyzed for HBsAg using five of the
most popular commercial ELISA kits in China; Zhu Hai
LivZon Diagnostic INC (LZ), Beijing WanTai Biological
Pharmacy Enterprise Limited Company (WT), Beijing
Big-GBI Biotech Limited Company (GBI), Beijing Bio-
Neovan Limited Company (BN), and Shenzhen Kang
Sheng Bao Bio-Technology Limited Company (KSB).
The ability of each of the ELISA to detect immune-
escaped mutants (sT118M, sG145R, sG145K) had been
confirmed in previous experiments (unpublished data).
All assays were performed according to the manufac-
turer’s instructions.
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The slope of each titration curve, which is proportional
to the average antibody avidity [40-42], was determined
and compared for the statistical difference using the
Fisher’s exact test.
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